Biogen beats Q3 estimates, raises guidance floor on growth

Biogen reported Q3 2026 revenue of $2.80 billion, exceeding estimates by 6.4% and growing 10.6% year-on-year. Adjusted EPS was $2.62, a 32.5% beat. Management raised full-year adjusted EPS guidance to $12.60. Free cash flow margin declined to 24.3% from 48.4% year-on-year.

Biogen (BIIB) reported a Q3 loss of $20.6M, down from a $466.5M profit last year, despite an 11% revenue increase to $2.8B. Adjusted EPS was $2.62, down from $4.81. The loss was driven by transaction-related charges. Biogen raised its low-end FY26 EPS outlook to $12.20-$13.00, up from $12.00-$13.00. Shares were down 0.29% in premarket trading.

Biogen (BIIB) reported Q3 2026 revenue of $2.8B, beating estimates by $170M. MS product revenue reached $919M, exceeding projections. Spinraza outperformed with $461M in sales. Syfovre and Empaveli, from the Apellis acquisition, contributed $191M and $52M respectively. Leqembi sales were $202M, slightly below consensus. Non-GAAP EPS fell 46% YoY to $2.62, but beat estimates. Biogen raised its full-year earnings outlook.

Biogen reported 3Q 2026 revenue of $2.8B, up 10.6% YoY, with a net loss of $20.6M compared to a $466.5M profit a year earlier. Growth in rare disease and immunology products offset declines in multiple sclerosis sales. The company expects MS revenue to continue declining.

Biogen reported Q3 2026 revenue of $2.8B, up 11% YoY, with non-GAAP EPS of $2.62. GAAP net loss was $20.6M due to transaction-related charges. The company raised its full-year non-GAAP EPS guidance to $12.20–$13.00. Growth was driven by its acquired Apellis products and strong performance from SPINRAZA, LEQEMBI, and SYFOVRE.

Biogen reported Q3 Non-GAAP EPS of $2.62, exceeding estimates by $0.63. Revenue reached $2.8B, up 10.2% year-over-year, surpassing expectations by $170M. The company's Growth Portfolio revenue grew 49% year-over-year to $1.26B, driven by the Apellis acquisition. Biogen also raised its FY26 outlook.